SEVEN SEAS – GLUCOSAMINE HEALTH CLAIM REJECTED IN THE UK
Since the rejection of glucosamine by EFSA as being able beneficially impact inflammation or support joints heath in the normal healthy population (EFSA Journal 2009; 7(9):1264) the market in Europe has been concerned. In the UK the MHRA have been looking to remove products claiming any relation to pain treatment and in Germany the courts had used injunctions to remove glucosamine containing products from shelf.
In the latest hit on Glucosamine the UK’s largest glucosamine company has been to alter its marketing claims as they are not compliant, according to the Advertising Standards Authority (ASA).
A national press ad for Seven Seas JointCare Opti-Release was headed, “Want smooth working joints throughout the day?*”. Below the text was an image of a woman running with glowing points at some of her joints. Text next to a picture of the product stated “Try new Seven Seas JointCare Opti-Release for a sustained release of glucosamine that’s in rhythm with your body”. Small print stated, “*Glucosamine occurs naturally in the body where it plays a role in the smooth working of the joints and helps maintain connective tissues. Seven Seas JointCare Opti-Release is one of a number of products including Seven Seas Joint Care Sport with Omega 3″.
The complainant challenged whether the ad was misleading because it implied that the efficacy of the product to improve joint health and mobility could be substantiated.
Seven Seas Defence
Seven Seas Ltd (Seven Seas) pointed out that the CAP AdviceOnline guidance CAP accepted the claim “Glucosamine occurs naturally in the body where it plays a role in the smooth working of the joints and helps maintain connective tissues”. They claimed the headline claim in the ad was an abbreviation of this and because they annotated the full claim in the small print, they did not consider the ad misleading. They claimed the ad did not imply that the efficacy of the product in improving joint health and mobility could be substantiated.
ASA Ruling
The ASA noted the CAP AdviceOnline guidance made clear that the ASA had not seen sufficient substantiation for claims that glucosamine could help maintain healthy joints or aid joint mobility. We considered that the heading “Want smooth working joints throughout the day?” implied the product improved joint health and mobility. Because we have not seen adequate substantiation to support this claim, we concluded that the ad was misleading.
The ad breached CAP Code (Edition 12) rules 3.1 (Misleading advertising) and 12.1 (Medicines, medical devices, health-related products and beauty products). The ad must not appear again in its current form.
TAKE HOME CONCERNS
The ruling suggests that enforcement (at least in the UK) of any health claims allowed by EFSA may be given little allowance for interpretation (flexibility in wording) and as such manufacturers could well be stuck with non-friendly consumer products claims in 2012.








